Background Treatment with dasatinib, a highly potent BCR-ABL kinase inhibitor, has
resulted in high rates of complete cytogenetic response and progression-free survival
among patients with chronic myeloid leukemia (CML) in the chronic phase, after failure of
imatinib treatment. We assessed the efficacy and safety of dasatinib, as compared with
imatinib, for the first-line treatment of chronic-phase CML. Methods In a multinational study,
519 patients with newly diagnosed chronic-phase CML were randomly assigned to receive …

Dasatinib is a highly potent BCR-ABL inhibitor with established efficacy and safety in
imatinib-resistant/-intolerant patients with chronic myeloid leukemia (CML). In the phase 3
DASISION trial, patients with newly diagnosed chronic-phase (CP) CML were randomized to
receive dasatinib 100 mg (n= 259) or imatinib 400 mg (n= 260) once daily. Primary data
showed superior efficacy for dasatinib compared with imatinib after 12 months, including
significantly higher rates of complete cytogenetic response (CCyR), confirmed CCyR …